A review of the preclinical and clinical evidence for protein kinase C as a target for drug development for bipolar disorder

Current Psychiatry Reports

Volumn 10, Issue 6, 2008, Pages 510-519

  DiazGranados, Nancy ^b   Zarate Jr , Carlos A ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE; FLUPHENAZINE; LITHIUM SALT; LORAZEPAM; MEDROXYPROGESTERONE; PAROXETINE; PLACEBO; PROTEIN KINASE C; TAMOXIFEN; VALPROIC ACID;

ANOREXIA; BIPOLAR DISORDER; CLINICAL TRIAL; DEPRESSION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; DRUG TOLERABILITY; DRY SKIN; HAMILTON SCALE; HOT FLUSH; HUMAN; MANIA; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NEUROTRANSMISSION; PROTEIN FUNCTION; PSYCHOSIS; REMISSION; REVIEW; SUICIDE ATTEMPT;

ADULT; ANIMALS; ANTIMANIC AGENTS; BIPOLAR DISORDER; BRAIN; CONTROLLED CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG THERAPY, COMBINATION; DRUGS, INVESTIGATIONAL; FEMALE; HUMANS; LITHIUM CARBONATE; MALE; PROTEIN KINASE C; TAMOXIFEN; VALPROIC ACID;

EID: 58449101305     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-008-0081-7     Document Type: Review

References (32)

1. Judd LL, Akiskal HS, Schettler PJ, et al.: The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002, 59: 530-537.
2. Goodwin FK, Jamison KR: Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression, edn 2. New York: Oxford University Press; 2007.
3. Cerullo MA, Strakowski SM: The prevalence and significance of substance use disorders in bipolar type I and II disorder. Subst Abuse Treat Prev Policy 2007, 2: 29.
4. Fossey MD, Otto MW, Yates WR, et al.: Validity of the distinction between primary and secondary substance use disorder in patients with bipolar disorder: Data from the first 1000 STEP-BD participants. Am J Addict 2006, 15: 138-143.
5. Zarate CA Jr, Tohen M, Fletcher K: Cycling into depression from a first episode of mania: A case-comparison study. Am J Psychiatry 2001, 158: 1524-1526.
6. Sachs GS, Gardner-Schuster EE: Adjunctive treatment of acute mania: a clinical overview. Acta Psychiatr Scand Suppl 2007, 434: 27-34.
7. Fagiolini A, Chengappa KN: Weight gain and metabolic issues of medicines used for bipolar disorder. Curr Psychiatry Rep 2007, 9: 521-528.
8. Manji HK, Zarate CA: Molecular and cellular mechanisms underlying mood stabilization in bipolar disorder: Implications for the development of improved therapeutics. Mol Psychiatry 2002, 7(Suppl 1): S1-S7.
9. Manji HK, Lenox RH: Ziskind-Somerfeld Research Award. Protein kinase C signaling in the brain: Molecular transduction of mood stabilization in the treatment of manic-depressive illness. Biol Psychiatry 1999, 46: 1328-1351.
10. Calabrese B, Halpain S: Essential role for the PKC target MARCKS in maintaining dendritic spine morphology. Neuron 2005, 48: 77-90.
11. Craske ML, Fivaz M, Batada NN, Meyer T: Spines and neurite branches function as geometric attractors that enhance protein kinase C action. J Cell Biol 2005, 170: 1147-1158.
12. Friedman E, Hoau Yan W, Levinson D, et al.: Altered platelet protein kinase C activity in bipolar affective disorder, manic episode. Biol Psychiatry 1993, 33: 520-525.
13. Wang HY, Friedman E: Enhanced protein kinase C activity and translocation in bipolar affective disorder brains. Biol Psychiatry 1996, 40: 568-575.
14. Manji HK, Bebchuk JM, Moore GJ, et al.: Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications. J Clin Psychiatry 1999, 60(Suppl 2): 27-39; discussion 40-41, 113-116.
15. Einat H, Yuan P, Szabo ST, et al.: Protein kinase C inhibition by tamoxifen antagonizes manic-like behavior in rats: Implications for the development of novel therapeutics for bipolar disorder. Neuropsychobiology 2007, 55: 123-131.
16. Harrison-Read PE: Models of mania and antimanic drug actions: progressing the endophenotype approach. J Psychopharmacol 2008 Jun 26 (Epub ahead of print).
17. Giambalvo CT: Protein kinase C and dopamine transport-2. Effects of amphetamine in vitro. Neuropharmacology 1992, 31: 1211-1222.
18. Giambalvo CT: Protein kinase C and dopamine transport'1. Effects of amphetamine in vivo. Neuropharmacology 1992, 31: 1201-1210.
19. Gnegy ME, Hong P, Ferrell ST: Phosphorylation of neuromodulin in rat striatum after acute and repeated, intermittent amphetamine. Brain Res Mol Brain Res 1993, 20: 289-298.
20. Gould TD, Einat H: Animal models of bipolar disorder and mood stabilizer efficacy: A critical need for improvement. Neurosci Biobehav Rev 2007, 31: 825-831.
21. Jordan VC: Molecular mechanisms of antiestrogen action in breast cancer. Breast Cancer Res Treat 1994, 31: 41-52.
22. Bebchuk JM, Arfken CL, Dolan-Manji S, et al.: A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania. Arch Gen Psychiatry 2000, 57: 95-97.
23. Young RC, Biggs JT, Ziegler VE, Meyer DA: A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978, 133: 429-435.
24. Kulkarni J, Garland KA, Scaffidi A, et al.: A pilot study of hormone modulation as a new treatment for mania in women with bipolar affective disorder. Psychoneuroendocrinology 2006, 31: 543-547.
25. Yildiz A, Guleryuz S, Ankerst DP, et al.: Protein kinase C inhibition in the treatment of mania: A double-blind, placebo-controlled trial of tamoxifen. Arch Gen Psychiatry 2008, 65: 255-263.
26. Zarate CA Jr, Singh JB, Carlson PJ, et al.: Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: A pilot study. Bipolar Disord 2007, 9: 561-570.
27. Tohen M: Clinical trials in Iipolar mania: implications in study design and drug development. Arch Gen Psychiatry 2008, 65: 252-253.
28. Keck PE Jr, Marcus R, Tourkodimitris S, et al.: A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003, 160: 1651-1658.
29. Sysko R, Walsh BT: A systematic review of placebo response in studies of bipolar mania. J Clin Psychiatry 2007, 68: 1213-1217.
30. Lopez M, Lelliott CJ, Tovar S, et al.: Tamoxifen-induced anorexia is associated with fatty acid synthase inhibition in the ventromedial nucleus of the hypothalamus and accumulation of malonyl-CoA. Diabetes 2006, 55: 1327-1336.
31. Palmer JT, Payne JL: Stabilization of hypomania following initiation of tamoxifen. Am J Psychiatry 2008, 165: 650-651.
32. Zarate CA Jr, Singh J, MTnji HK: Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry 2006, 59: 1006-1020.